Nesfatin-1 and ghrelin levels in serum and saliva of epileptic patients: hormonal changes can have a major effect on seizure disorders

Simple item page
dc.contributor.authorAydin, S
dc.contributor.authorDag, E
dc.contributor.authorOzkan, Y
dc.contributor.authorErman, F
dc.contributor.authorDagli, AF
dc.contributor.authorKilic, N
dc.contributor.authorSahin, I
dc.contributor.authorKaratas, F
dc.contributor.authorYoldas, T
dc.contributor.authorBarim, AO
dc.contributor.authorKendir, Y
dc.date.accessioned2024-07-18T12:03:52Z
dc.date.available2024-07-18T12:03:52Z
dc.description.abstractNesfatin-1 and ghrelin are the two recently discovered peptide hormones involved in the control of appetite. Besides its main appetite-control function, ghrelin also has anticonvulsant effects, while nesfatin-1 causes depolarization in the paraventricular nucleus (PVN). The aims of this study, therefore, were to investigate: (i) whether there are differences in the concentrations of nesfatin-1 and ghrelin in saliva and serum samples between eplilepsy patients and normal controls and (ii) whether salivary glands produce nesfatin-1. The study included a total of 73 subjects: 8 patients who were newly diagnosed with primary generalized seizures and had recently started antiepileptic drug therapy; 21 who had primary generalized seizures and were continuing with established antiepileptic drug therapy; 24 who had partial seizures (simple: n = 12 or complex: n = 12) and were continuing with established antiepileptic drug therapy; and 20 controls. Salivary gland tissue samples were analyzed for nesfatin-1 expression by immunochemistry and ELISA. Saliva and serum ghrelin levels were measured by ELISA and RIA, and nesfatin-1 levels by ELISA. Nesfatin-1 immunoreactivity was detected in the striated and interlobular parts of the salivary glands and the ducts. The nesfatin-1 level in the brain was around 12 times higher than in the salivary gland. Before antiepileptic treatment, both saliva and serum nesfatin-1 levels were around 160-fold higher in patients who are newly diagnosed with primary generalized epilepsy (PGE) than in controls; these levels decreased with treatment but remained about 10 times higher than the control values. Saliva and serum nesfatin-1 levels from patients with PGE and partial epilepsies who were continuing antiepileptic drugs were also 10-fold higher than control values. Serum and saliva ghrelin levels were significantly (twofold) lower in epileptic patients before treatment than in controls; they recovered somewhat with treatment but remained below the control values. These results suggest that the low ghrelin and especially the dramatically elevated nesfatin-1 levels might contribute to the pathophyisology of epilepsy. Therefore, serum and saliva ghrelin and especially the remarkably increased nesfatin-1 might be candidate biomarkers for the diagnosis of epilepsy and for monitoring the response to anti-epileptic treatment.
dc.identifier.issn0300-8177
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/9416
dc.language.isoEnglish
dc.publisherSPRINGER
dc.subjectBLOOD-BRAIN-BARRIER
dc.subjectSATIETY MOLECULE
dc.subjectPLASMA
dc.subjectNEURONS
dc.subjectHYPOTHALAMUS
dc.subjectVASOPRESSIN
dc.subjectOXYTOCIN
dc.subjectNUCLEUS
dc.subjectLEPTIN
dc.subjectGROWTH
dc.titleNesfatin-1 and ghrelin levels in serum and saliva of epileptic patients: hormonal changes can have a major effect on seizure disorders
dc.typeArticle; Proceedings Paper

Files

Collections

Web of Science Koleksiyonu